Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study

1

The study evaluated the efficacy and safety of academic anti-CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas.
2

A total of 76 patients were enrolled, with a median age of 47 years, treated at the N.N. Alexandrov National Cancer Centre in Belarus.
3

Complete response was achieved in 57.5% of patients, with a 4-year event-free survival rate of 46.2% and overall survival rate of 67%.
4

Among patients with follicular lymphoma, the complete response rate was 83.3%, and the 4-year event-free survival was 81.7%.
5

Cytokine release syndrome occurred in 43.4% of patients, with acceptable toxicity levels and no grade 4 cases reported.

Frontiers In Oncology

by Natalya E. Konoplya, Tatiana M. Doroshenko, Katsiaryna Yu. Zharkova, Tatyana V. Savich, Ihar M. Seviaryn, Nadezhda M. Bobrova, Alexey A. Beleevsky, Eldar Kh. Sarydze, Sergey L. Polyakov
July 17, 2026

1